Quantum Biopharma annual stock-based compensation
2019
2020
2021
2022
2023
2024
2025
Quantum Biopharma Stock-Based Compensation Growth & History (QNTM)
Quantum Biopharma's stock-based compensation was $2.9M for fiscal 2025.
View full Quantum Biopharma company overviewQuantum Biopharma annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $2.9M | $2.8M | +1835.11% |
| 2024 | 2024-12-31 | $152,214 | −$3.7M | −96.03% |
| 2023 | 2023-12-31 | $3.8M | $2.3M | +150.48% |
| 2022 | 2022-12-31 | $1.5M | −$5.9M | −79.43% |
| 2021 | 2021-12-31 | $7.4M | −$608,081 | −7.55% |
| 2020 | 2020-12-31 | $8.1M | −$4.0M | −33.36% |
| 2019 | 2019-12-31 | $12.1M | — | — |
Quantum Biopharma quarterly stock-based compensation
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $13,449 | −$836,135 | −98.42% |
| Q1 2026 | 2026-03-31 | $892,057 | $600,785 | +206.26% |
| Q4 2025 | 2025-12-31 | $808,452 | — | — |
| Q3 2025 | 2025-09-30 | $996,194 | $930,770 | +1422.67% |
| Q2 2025 | 2025-06-30 | $849,584 | $738,060 | +661.79% |
| Q1 2025 | 2025-03-31 | $291,272 | $233,529 | +404.43% |
| Q3 2024 | 2024-09-30 | $65,424 | −$60,739 | −48.14% |
| Q2 2024 | 2024-06-30 | $111,524 | −$291,869 | −72.35% |
| Q1 2024 | 2024-03-31 | $57,743 | — | — |
| Q3 2023 | 2023-09-30 | $126,163 | — | — |
| Q2 2023 | 2023-06-30 | $403,393 | — | — |
Quantum Biopharma stock-based compensation trends
Over the last five fiscal years, Quantum Biopharma's stock-based compensation decreased from $8.1M to $2.9M, a change of −$5.1M. The latest reported quarter, Q2 2026, shows $13,449.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Quantum Biopharma source filings ↗